Curriculum Vitae Lars Rönnstrand

Translational Cancer Research and Lund Stem Cell Center, Dept. of Laboratory Medicine, Lund University, Medicon Village, Lund
http://www.ronnstrandlab.com

Higher Education qualification(s):
BSc in Chemistry, Lund University 1982
Biomedical Education, Uppsala University, 1982

Degree of Doctor:
1989; Medical and Physiological Chemistry, Uppsala University; "Purification, characterization and studies on the in vivo distribution of the B-type receptor for platelet derived growth factor". Supervisor: Prof. Carl-Henrik Heldin.

Postdoctoral Positions:
1989-1990 Memorial Sloan-Kettering Cancer Center, New York, USA (mentor: Joan Massagué)
1991-1993 Ludwig Institute for Cancer Research, Uppsala (mentor: Carl-Henrik Heldin)

Qualification required for appointment as a docent:
1994 Uppsala University (Molecular Cell Biology)

Present Position:
Professor of Molecular Medicine, Dept. of Laboratory Medicine, Lund,
Lund University 2002-present

Previous Positions and periods of appointment:
Assistant Member, Ludwiginst. f. Cancer Research, Uppsala 1993-1999
Associate Member, Ludwig Inst. f. Cancer Res., Uppsala 1999-2002
Higher researcher position in ”Growth factors and their mechanism action” funded by Swedish Research Council 2000-2005

Interruption in research
Parental leave 4 months, May-August 1999

Supervision: PhD students as principal supervisor
Simon Ekman (2000); Johan Lennartsson (2002); Anders Kallin (2003); Malin Pedersen (2009); Kristina Masson (2009); Elena Razumovskaya (2011); Bengt Phung (2013); Oscar Lindblad (2016); Sausan Moharram, accepted as PhD student 2016; Marisse Asong, accepted as PhD student 2018.

Supervision: Postdocs as principal supervisor
Osamu Kozawa 941018-950811; Kerstin Thömmes 960601-980331; Muhammad Emaduddin 970619-990131; Akira Mogi 980601-000531; Patrik Wollberg 971117-000731; Enrico Bracco 000101-010831; Oleksandr Voytyuk 000801-041231; Jean-Baptiste Demoulin 001115-020801; Federica Chiara 020211-020801;Torben Österlund 021001-040931; Elke Heiss 030601-050801; Christina Sundberg 030901-060901; Tao Liu 051001-070425; Rasheed Khan 071001-091014; Clara Isabel Aceves 090901-100901; Shruti Agarwal,

101201- 120901; Tine Thingholm 2011-2013; Sachin Raj, 160315-170601; Julhash U. Kazi 100308-150101; Jianmin Sun 041001-present; Rohit Chougule, 140908-present;

Thesis examination
PhD thesis Faculty Examiner at 18 PhD dissertations: Birgitte Ursø Hagedorn Research Institute, Copenhagen, 1996; Elisabeth Douglas Galsgaard, Hagedorn Research Institute, Copenhagen, 1997; Lena Stenson-Holst, Department of Cell and Molecular Biology, Lund, 1998; Jan Amstrup, Hagedorn Research Institute, Copenhagen, 1999; Nikolaj Blom. Technical University of Denmark, Copenhagen, 1999; Anna Karina Busch, Hagedorn Research Institute, Copenhagen, 1999; Lone Finnerup Juhl, Hagedorn Research Institute, Copenhagen, 1999; Jannik Andersen, Panum Institute, Copenhagen, 2001; Leonard Girnita, Karolinska Institute, 2002; Marie Henriksson, Umeå University 2003; Hong Xu, Karolinska Institute 2006; Eystein Oveland, Bergen, Norway 2008; Stine Skovbo Olsen, Copenhagen May 2010; Mats Dehlin, Gothenburg, 2012; Bo Rafn, Copenhagen May 17, 2013; Alamdar Hussain, Karolinska Institute June 13, 2013; Christina Dahl, Copenhagen March 24, 2014; Manuela Gustafsson, Karolinska Institute. September 9, 2017.

Grant reviewing
Member of Evaluation Committee F2 Swedish Research Council 2009 and 2011; Member of Evaluation Committee F1 Swedish Research Council 2012 and 2017; Chairman of Evaluation Committee F1 Swedish Research Council 2018. Member of evaluation committee Norwegian Cancer Foundation 2018. Member of evaluation committee for cancer applications to the Norwegian Research Council 2004; Ad hoc reviewer for several research organizations, including Association for International Cancer Research (AICR), Swiss National Science Foundation, The Academy of Finland, Research Council for Health and Research Council for Environment and Natural Resources, Italian Cancer Foundation, Belgian Cancer Foundation, North West Cancer Research Fund (UK), STINT, French National Cancer Institute, Fonds National de la Recherche Luxembourg, Deutsche Forschungsgemeinschaft, The Wellcome Trust, Leukaemia & Lymphoma Research (UK) Swedish Research Council-Natural Sciences, Karolinska Institute (evaluation of junior researcher positions) 2011, 2013-2017, Bergen Research Foundation (Norway), Cancer Research UK, Cancer Research Wales,

Expert Witness
- Expert Witness in the patent infringement litigation T-833-11 Apotex Inc. v. Novartis AG. September, 2012 Toronto, Canada. This process dealt with the Canadian patent of Gleevec.
- Expert Witness in the patent litigation T-2021-10 Teva Canada Limited v. Novartis AG. September, 2012 Toronto, Canada. This process dealt with the Canadian patent of Gleevec.

Connections with industry

Advisor for BioMarin Pharmaceuticals, San Rafael, California 2014
Advisory Board Member, OncoSignature AB 2016-
Advisory Board Member, Acrivon Therapeutic 2018-
Founder and chairman, PhosphoDynamics AB 2016-

Patents
U.S. Patent No: 5,229,495: Ichijo H, Miyazono K, Rönnstrand L, Hellman U, Wernstedt C and Heldin CH “Substantially pure receptor like TGF-beta binding molecules and uses thereof”. 1993-07-19; U.S. Patent No: 5,578,703: Ichijo H, Miyazono K, Rönnstrand L, Hellman U, Wernstedt C and Heldin CH “Substantially pure receptor like TGF-beta1 binding

molecules." 1996-11-25; US Patent No: 5,731,200: Ichijo H, Miyazono K, Rönnstrand L, Hellman U, Wernstedt C and Heldin CH "Isolated nucleic acid encoding receptor-like TGF-beta1 binding protein." 1998-03-23

Publications

In total 149 publications (PubMed 18-06-19). Web of Science: 192 publications (18-06-19), 88576 citations, H-index 49. Google Scholar Citations: 205 publications, 12179 citations, H-index 58.

GOOGLE SCHOLAR CITATIONS

Web of Science



Publications per year Citations per year

List of publications

Original publications

1. Moharram SA, Shah K, Khanum F, **Rönnstrand L** and Kazi JU (2018) The ALK inhibitor ADZ3463 displays efficacy against acute leukemia. Manuscript

2. Li T, Deng Y, Shi Y, Tian R, Chen Y, Zou L, Kazi JU, **Rönnstrand L**, Feng B, Chan SO, Chan W-Y, Sun J, and Zhao H (2018) Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma. **Oncogene** In press.

3. Sun J, Thingholm T, Højrup P and **Rönnstrand L** (2018) XK-related protein 5 (XKR5) is a novel negative regulator of KIT/D816V-mediated transformation. **Oncogenesis** 7(6): 48

4. Hyrenius-Wittsten A, Pilheden M, Sturesson H, Hansson J, Walsh MP, Song G, Kazi JU, Liu J, Ramakrishnan R, Garcia Ruiz C, Nance S, Gupta P, Zhang J, **Rönnstrand L**, Hultquist A, Downing JR, Lindkvist-Petersson K, Paulsson K, Järås M, Gruber TA, Ma J and Andersson AK (2018) *De novo* activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. **Nat Commun** 9(1):1770

5. Rupar K, Moharram SA, Kazi JU and **Rönnstrand L** (2018) Src-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation. **Sci Rep** 8(1): 6405

6. Marhäll A, Heidel F, Fischer T, Rönnstrand L.(2018) Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation. **Ann Hematol** 97(5): 773-780

7. Marhäll A, Kazi JU and **Rönnstrand L** (2017) The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation. **Sci Rep** 7, 13734

8. Phung B, Kazi JU, Lundby A, , Bergsteinsdottir K, Sun J, Goding CR ,Jönsson G, Olsen JV, Steingrímsson E and **Rönnstrand L.** (2017) KITD816V induces SRC-mediated tyrosine phosphorylation of MITF and altered transcription program in melanoma. **Mol Cancer Res** 15, 1265-1274

9. Kazi JU, Chougule RA, Li T, Su X, Moharram SA, Rupar K, Marhäll A, Gazi M, Sun J, Zhao H and **Rönnstrand L** (2017) Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD. **Cell Mol Life Sci.** 74, 2679-2688

10. Kazi, JU, Rupar K, Marhäll A, Moharram, SA, Khanum F, Shah K, Mohiuddin G, Nagaraj SRM, Sun J, Chougule RA, **Rönnstrand L** (2017). ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling. **Oncotarget**. 8, 12194-12202

11. Moharram SA, Chougule RA, Su X, Li, T, Sun J, Zhao H, **Rönnstrand L** and Kazi JU (2016) Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling. **Oncotarget;** 7, 57770-82

12. Lindblad O, Cordero E, Puissant A, Macaulay L, Kabir NN, Sun J, Haraldsson K, Borg Å, Levander F, Stegmaier K, Pietras K, **Rönnstrand L** and Kazi JU. (2016) Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to FLT3 Inhibition in AML. **Oncogene**; 35, 5119-31

13. Chougule, RA, Cordero, E, Moharram SA, Pietras K, **Rönnstrand L** and Kazi JU (2016) Expression of GADS enhances FLT3-induced mitogenic signaling. **Oncotarget.** 7, 14112-24

14. Alam MW, Persson CU, Reinbothe S, Kazi JU, **Rönnstrand L**, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S and Jögi A (2016) HIF2alpha contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells. **Oncotarget**. 7, 11238-50

15. Chougule R, Kazi JU and **Rönnstrand L** (2016) FYN expression potentiates FLT3-ITD-induced STAT5 signaling in acute myeloid leukemia. **Oncotarget**. 7, 9964-74

16. Lindblad O, Chougule R, Moharram SA, Kabir NN, Sun J, Kazi JU and **Rönnstrand L** (2015) The role of HOXB2 and HOXB3 in acute myeloid leukemia. **Biochem Biophys Res Commun.** 467, 742-7

17. Zhang J, Vakhrusheva O, Bandi SR, Demirel Ö, Kazi JU, Gomes Fernandes R, Jakobi K, Eichler A, **Rönnstrand L**, Rieger M, Carpino N, Serve H and Brandts CH.(2015) STS1 and STS2 are key regulators of hematopoietic stem and progenitor cells. **Stem Cell Reports** 5, 633-646

18. Lindblad O, Li T, Su X, Sun J Kabir NN, Levander F, Zhao H, Lu G, **Rönnstrand L** and Kazi JU (2015) BEX1 acts as a tumor suppressor in acute myeloid leukemia. **Oncotarget** 6, 21395-405

19. Lindblad O, Kazi JU, **Rönnstrand L**, Sun J.(2015) PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner**. Cell Mol Life Sci** 72, 4399-407

20. Agarwal S, Kazi JU, Mohlin S, Påhlman S and **Rönnstrand L** (2015) The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V. **Oncogene** 34, 4581-90

21. Kabir NN, **Rönnstrand L** and Kazi JU. (2014) Keratin 19 expression correlates with poor prognosis in breast cancer. **Mol Biology Rep**. 41, 7729-35

22. Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, **Rönnstrand L**, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, Hemann MT and Stegmaier, K (2014) SYK is a critical regulator of FLT3 in acute myeloid leukemia. **Cancer Cell**. 25, 226–242

23. Reinbothe S, Larsson AM, Vaapil M, Wigerup C, Sun J, Jögi A, Neumann D, **Rönnstrand L**, Påhlman S. (2014) EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation **Biochem Biophys Res Commun** 445, 163-9. 2014

24. Kazi JU, Agarwal S, Sun J, Bracco E, and **Rönnstrand L**. (2014) Src-Like Adaptor Protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling. **J Cell Sci.** 127, 653-662

25. Sun J, Mohlin S, Lundby A, Hellman U, Påhlman S, Olsen JS and **Rönnstrand L** (2014) The PI3-kinase isoform p110delta is essential for D816V/c-Kit mediated tumor formation in a manner independent of its lipid kinase activity. **Oncogene**. 33, 5360-9

26. Phung B, Steingrímsson E and **Rönnstrand L** (2013) Differential activity of c-KIT splice forms is controlled by extracellular peptide insert length. **Cell Signal** 25, 2231-8

27. Kabir NN, **Rönnstrand L**, Kazi JU (2013) The basic helix-loop-helix (bHLH) proteins in breast cancer progression. **Med Oncol** 30, 666. Letter

28. Agarwal S, Kazi JU, **Rönnstrand L.** (2013) Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation. **J. Biol. Chem.** 288, 22460-8

29. **Rönnstrand L**, Phung B. (2013) Enhanced SOX10 and KIT expression in cutaneous melanoma. **Med Oncol** 30, 648. Letter

30. Kazi JU, Vaapil M, Agarwal S, Bracco E, Påhlman S, **Rönnstrand L.** (2013) The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. **Cell Signal** 25, 1852-60

31. Kazi JU, Sun J and **Rönnstrand L** (2013) Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. **Mol Oncol** 7, 693-703

32. Kazi JU, Sun J and **Rönnstrand L** (2013) The presence or absence of IL-3 during long-term culture of Flt3-ITD and c-Kit-D816V expressing Ba/F3 cells influences signaling outcome. **Exp Hematol** 41, 585-7. Letter

33. Kabir NN, **Rönnstrand L** and Kazi JU (2013) Deregulation of protein phosphatase expression in acute myeloid leukemia. **Med Oncol** 30, 517. Letter

34. Kabir NN, **Rönnstrand L** and Kazi JU (2013) Protein Kinase C expression is deregulated in chronic lymphocytic leukemia. **Leuk Lymphoma** 54, 2288-90

35. Kabir NN, **Rönnstrand L** and Kazi JU (2013) FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL) **Med Oncol** 30, 462. Letter

36. Kazi JU and **Rönnstrand L** (2012) Src-like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling. **PLOS One**. 7, e53509

37. Kazi JU and **Rönnstrand L** (2012) FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia. **Mol Oncol** 7, 402-18

38. Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, **Rönnstrand L.**(2012) Suppressor of Cytokine Signaling 6 (SOCS6) Negatively Regulates Flt3 Signal Transduction through Direct Binding to Phosphorylated Tyrosines 591 and 919 of Flt3. **J. Biol. Chem.** 287, 36509-17

39. Lin DC, Yin T, Koren-Michowitz M, Ding LW, Gueller S, Gery S, Tabayashi T, Bergholz U, Kazi JU, **Rönnstrand L**, Stocking C, Koeffler HP.(2012) Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. **Blood** 120, 3310-7

40. Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander SK, **Rönnstrand L**, Götzke KS, Peschel C and Duyster J (2012) SRC is a signaling mediator in FLT3-ITD but not in FLT3-TDK positive-AML. **Blood**. 119, 4026-33

41. Munksgaard Persson M, Johansson ME, Monsef N, Planck M, Beckman S, Seckl M, **Rönnstrand L**, Påhlman S, Pettersson HM. (2012) HIF-2α expression is suppressed in SCLC cells, which survive at moderate and severe hypoxia by HIF-independent mechanisms. **Am. J. Pathol.** 180, 494-504

42. Heidel FH, Razumovskaya E, Mack TS, Blum M-C, Lipka DB, Ballaschk A, Borrmann A-K, Kramb J-P, Plutizki S, **Rönnstrand L**, Dannhardt G and Fischer T (2012) 3,4-Diarylmaleimides – a novel class of kinase inhibitors effectively induce apoptosis in FLT3-ITD dependent cells. **Ann Hematol**. 91, 331-44

43. Phung B, Sun J, Steingrimsson E, **Rönnstrand L.** (2011) C-Kit Signaling Depends on Microphthalmia- Associated Transcription Factor for Effects on Cell Proliferation. **PLoS ONE**. 6, e24064

44. Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, **Rönnstrand L**, Walz TM, Jönsson JI. (2011) Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice **Brit J Haematol** 155, 198-208

45. Razumovskaya E, Sun J and **Rönnstrand L** (2011) Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD. **Biochem Biophys Res Commun** 412, 307-312

46. Kharazi S, Mead AJ, Mansour A, Hultquist A, Böiers C, Luc S, Buza-Vidas N, Ma Z, Ferry H, Atkinson D, Reckzeh K, Masson K, Cammenga J, **Rönnstrand L**, Arai F, Suda T, Nerlov C, Sitnicka E, Jacobsen SE (2011) Impact of gene dosage, loss of wild type allele and FLT3 ligand on Flt3-ITD induced myeloproliferation **Blood** 118, 3613-21

47. Arora D, Stopp S, Böhmer SA, Schons J, Godfrey R, Masson K, Razumovskaya E, **Rönnstrand L**., Böhmer FD and Müller JP (2011) Protein tyrosine phosphatase Dep-1 controls receptor tyrosine kinase FLT3 signalling **J. Biol. Chem**. 286, 10918-29

48. Al-Zadjali F, Pike AC, Vesterlund M, Sun J, Wu C, **Rönnstrand L**, Knapp S, Bullock AN and Flores-Morales A (2011) Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. **J. Biol. Chem.** 286, 480-490

49. Razumovskaya E, Masson K, Khan R, Bengtsson S and **Rönnstrand L** (2009) Oncogenic Flt3 receptors display different specificity and kinetics of autophoshorylation. **Exp Hematol.** 37, 979-89

50. Masson K, Liu T, Sun J and **Rönnstrand L** (2009) A role of Gab2 association in Flt3-ITD mediated STAT5 phosphorylation and cell survival. **Br J Haematol** 146, 193-202

51. Sun J, Pedersen M, and **Rönnstrand L** (2009) The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction. **J. Biol. Chem.** 284, 11039-11047

52. Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Böhmer FD, Masson K, **Rönnstrand L**, Huber C, Kindler T and Fischer T (2009) A novel Molecular Mechanism of Primary Resistance to FLT3-Kinase Inhibitors in Acute Myeloid Leukemia. **Blood** 113, 4063-4073

53. Pedersen M, **Rönnstrand L**, and Sun J (2009) The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. **Cell Signal.** 21, 413-418

54. Pedersen M, Löfstedt T, Sun J, Holmquist-Mengelbier L, Påhlman S and **Rönnstrand L** (2008) Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells. **Biochem Biophys Res Commun.** 377, 98-103

55. Sun J, Pedersen M and **Rönnstrand L** (2008) GAB2 is involved in differential PI3-kinase signaling by two splice forms of c-Kit. **J. Biol. Chem.** 283, 27444-27451

56. Ceder JA, Jansson L, Ehrnström RA, **Rönnstrand L**, Abrahamsson PA (2008) The characterization of epithelial and stromal subsets of candidate stem/progenitor cells in the human adult prostate. **Eur Urol** 53, 524-31

57. Sun J, Pedersen M, Bengtsson S and **Rönnstrand L** (2007) Grb2 mediated Cbl recruitment to the stem cell factor receptor/c-Kit mediates ubiquitination, internalization and degradation of c-Kit. **Exp Cell Res** 313, 3935-42

58. Edling CE, Pedersen M, Carlsson L, **Rönnstrand L**, Palmer RH, and Hallberg B (2007) Hematopoietic progenitor cells and mast cells utilize conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation. **Br. J. Haematol.** 136, 260-8

59. Masson K, Heiss E, Band, H. and **Rönnstrand L** (2006) Direct binding of Cbl to pY568 and pY936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. **Biochem. J.** 399, 59-67

60. Heiss E, Masson, K., Sundberg, C., Pedersen M, Sun J, Bengtsson S and **Rönnstrand L** (2006) Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. **Blood** 108, 1542-1550

61. Rebholtz, H., Panasuyk, G., Fenton, T., Nemazanyy, I., Valovka, T., Flajolet, M. **Rönnstrand, L.,** Stephens, L., West, A., and Gout, I.T (2006) Receptor association and tyrosine phosphorylation of S6 kinases. **FEBS J.** 273, 2023-2036

62. Théo-Anton, N., Tabone, S., Brouty-Boyé, D., Saffroy, R., **Rönnstrand, L.** Lemoine, A., and Emile, J.-F. (2006) Co expression of SCF and KIT in gastrointestinal stromal tumors (GISTs) suggests an autocrine/paracrine mechanism. **Br. J. Cancer** 94, 1180-1185

63. Hassel, S., Yakymovych, M, Hellman, U, **Rönnstrand, L**, Knaus, P and Souchelnytskyi, S (2006) Interaction and functional synergy between the serine/threonine kinase bone morphogenetic protein type II receptor with the tyrosine

kinase stem cell factor receptor stem cell factor receptor**" J. Cell Physiol.** 206, 457-467

64. Demoulin, J.-B., Ericsson, J., Kallin, A, Rorsman, C., **Rönnstrand, L.** and Heldin, C.-H. (2004) "Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory-element binding proteins". **J. Biol. Chem.** 279, 35392-35402

65. Kallin, A., Demoulin, J.-B., Nishida, K., Hirano, T., **Rönnstrand, L.** and Heldin, C.-H. (2004) "Gab1 contributes to cytoskeletal reorganization and chemotaxis in response to platelet-derived growth factor" **J. Biol. Chem.** 279, 17897-17904

66. Alvarado-Kristensson, M., Melander, F., Leandersson, K., **Rönnstrand, L.,** Wernstedt, C. and Andersson, T. (2004) p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils **J. Exp. Med.** 199, 449-458

67. Persson, C., Sävenhed, C., Bourdeau, A., Tremblay, M., Markova, B., Böhmer, F.D., Haj, F.G:, Neel, B.G., Heldin, C.-H., **Rönnstrand, L.,** Östman, A. and Hellberg, C. (2004) Deletion of TC-PTP results in site-selective increase in PDGF_induced receptor tyrosine phosphorylation and enhanced chemotactic response. **Mol. Cell Biol.** 24, 2190-2201

68. Neuschäfer-Rube, F., Hermosilla, R., Rehwald, M., **Rönnstrand, L**., Schülein, R., Wernstedt, C and Püschel, G.P. (2004)" Identification of a Ser/Thr cluster in the C-terminal domain of the human prostaglandin EP4-R essential for agonist-induced beta-arrestin 1-recruitment that differs from the apparent principal phosphorylation site **Biochem J.** 379, 573-585

69. Demoulin, J.-B., Kon Seo, J., Ekman, S., Grapengiesser, E., Engström, U., Hellman, U., **Rönnstrand, L.** and Heldin, C.-H. (2003) Ligand-induced recruitment of Na+/H+ exchanger regulatory factor to the platelet-derived growth factor (PDGF) receptor regulates actin cytoskeleton reorganization by PDGF **Biochem. J.** 376, 505-510

70. Ivanov KI, Puustinen P, Gabrenaite R, Vihinen H, **Rönnstrand L**, Valmu L, Kalkkinen N and Mäkinen K (2003) Phosphorylation of the potyvirus capsid protein by protein kinase CK2 and its relevance for virus infection **Plant Cell** 15, 2124-2139

71. Lennartsson J, Wernstedt C, Engström U, Hellman U and **Rönnstrand L** (2003) Identification of Tyr900 in the kinase domain of c-Kitas a Src-depenent phosphorylation site mediating interaction with c-Crk **Exp Cell Res** 288, 110-118

72. Lundin L, **Rönnstrand L**, Cross M, Hellberg C, Lindahl U, Claesson-Welsh L (2003) Differential tyrosine phosphorylation of fibroblastgrowth factor (FGF) receptor-1 and receptor proximal signal transduction in response to FGF-2 and heparin. **Exp Cell Res**, 287, 190-198

73. Sørensen CS, Syljuåsen RG, Falck J, Schroeder T, **Rönnstrand L**, Khanna KK, Zhou BB, Bartek J and Lukas J (2003) Chk1 regulates the S phase checkpoint by coupling

the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A **Cancer Cell** 3, 247-258

74. Markova B, Herrlich P, **Rönnstrand L** and Böhmer FD (2003) Identification of protein tyrosine phosphatases associating with the PDGF receptor **Biochemistry** 42, 2691-2699

75. Karger EM, Frolova OY, Fedorova NV, Baratova LA, Ovchinnikova TV, Susi P, Mäkinen K, **Rönnstrand L**, Dorokhov YL and Atabekov JG (2003) Dysfunctionality of a tobacco mosaic virus movement protein mutant mimicking threonine 104 phosphorylation **J Gen Virol** 84, 727-732

76. Nore B, Mattsson PT, Antonsson P, Bäckesjö, CM, Westlund A, Lennartsson J, Hansson H, Low P, **Rönnstrand L** and Smith CIE (2003) Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases **Biochem Biophys Acta** 1645, 123-132

77. Autero M, Heiska L, **Rönnstrand L**, Vaheri A, Gahmberg CG and Carpén O (2003) Ezrin is a substrate for Lck in T cells **FEBS Lett** 535, 82-86

78. Micke P, Basrai M, Faldum A, Bittinger F, **Rönnstrand L**, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R and Hengstler JG (2003) Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications **Clin Cancer Res** 9, 188-194

79. Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge S, Ashman LK and **Rönnstrand L** (2003) Src family kinases are involved in the differential signaling from two splice forms of c-Kit **J Biol Chem** 278, 9159-9166

80. Wollberg P, Lennartsson J, Gottfridsson E, Yoshimura A, **Rönnstrand L** (2003) The adapter protein APS associates with the multifunctional docking sites Tyr-568 and Tyr-936 in c-Kit **Biochem J** 370, 1033-1038

81. Hägg M, Liljegren A, Carlsson J, **Rönnstrand L** and Lennartsson J (2002) EGF and dextran-conjugated EGF induces differential phosphorylaton of the EGF receptor **Int J Mol Med** 10, 655-659

82. Ekman S, Kallin A, Engström U, Heldin CH and **Rönnstrand L** (2002) SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF beta-receptor **Oncogene** 21, 1870-1875

83. Palumbo R, Gaetano C, Antonini A, Pompilio G, Bracco E, **Rönnstrand L**, Heldin CH, Capogrossi MC (2002) Different effects of high and low shear stress on platelet-derived growth factor isoform release by endothelial cells: consequences for smooth muscle cell migration **Arterioscler Thromb Vasc Biol** 22, 405-411

84. Göransson O, Resjö S, **Rönnstrand L**, Manganiello V and Degerman E (2000) Ser-474 is the major target of insulin-mediated phosphorylation of protein kinase B beta in primary rat adipocytes **Cell Signal** 14, 175-182

85. Chian R, Young S, Danilkovitch-Miagkova A, **Rönnstrand L**, Leonard E, Ferrao P, Ashman L and Linnekin D (2001) Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant **Blood** 98, 1365-1373

86. Söderholm H, Olsson A, Lavenius E, **Rönnstrand L** and Nånberg E (2001) Activation of Ras, Raf-1 and protein kinase C in differentiating human neuroblastoma cells after treatment with phorbolester and NGF **Cell Signal** 13, 95-104

87. Hansen K, Farkas T, Lukas J, Holm K, **Rönnstrand L** and Bartek J (2001) Phosphorylation-dependent and -independent functions ofp130 cooperate to evoke a sustained G1 block **EMBO J** 20, 422-432

88. Anderson KE, Lipp P, Bootman M, Ridley SH, Coadwell J, **Rönnstrand L**, Lennartsson J, Holmes AB, Painter GF, Thuring J,Lim Z, Erdjument-Bromage H, Grewal A, Tempst P, Stephens LR and Hawkins PT (2000) DAPP1 undergoes PI3-kinase-dependent cycle of plasma-membrane recruitment and endocytosis upon cell stimulation **Curr Biol** 10, 1403-1412

89. Siegbahn A, Johnell M, Rorsman C, Ezban M, Heldin CH and **Rönnstrand L** (2000) Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis **Blood** 96, 3452-3458

90. Molander C, Kallin A, Izumi H, **Rönnstrand L** and Funa K (2000) TNF-alpha suppresses the PDGF beta-receptor kinase **Exp Cell Res** 258, 65-71

91. Thullberg M, Bartkova J, Khan S, Hansen K, **Rönnstrand L**, Lukas J, Strauss M and Bartek J (2000) Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors **FEBS Lett**. 470, 161-166

92. Sjöblom T, Boureux A, **Rönnstrand L**, Heldin CH, Ghysdael J and Östman A (1999) Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein **Oncogene** 18, 7055-7062

93. Lennartsson J, Blume-Jensen P, Hermanson M, Pontén E, Carlbeg M and **Rönnstrand L** (1999) Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor /c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction **Oncogene** 18, 5546-5553

94. **Rönnstrand L**, Siegbahn A, Rorsman C, Johnell M, Hansen K and Heldin CH (1999) Overactivation of phospholipase C-gamma1renders platelet-derived growth factor beta-receptor-expressing cells independent of the phosphatidylinositol 3-kinase pathway for chemotaxis **J Biol Chem** 274, 22089-22094

95. Emaduddin M, Ekman S, **Rönnstrand L** and Heldin CH (1999) Functional co-operation between the subunits in heterodimeric platelet-derived growth factor complexes **Biochem J** 341, 523-528

96. **Rönnstrand L**, Arvidsson AK, Kallin A, Rorsman C, Hellman U, Engström U, Wernstedt C and Heldin CH (1999) SHP-2 binds toTyr763 and Tyr1009 in the PDGF beta-receptor and mediates PDGF-induced activation of the Ras/MAP kinase pathway and chemotaxis **Oncogene** 18, 3696-3702

97. Thömmes K, Lennartsson J, Carlberg M and **Rönnstrand L** (1999) Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor **Biochem J** 341, 211-216

98. Ekman S, Thuresson ER, Heldin CH and **Rönnstrand L** (1999) Increased mitogenicity of an alphabeta heterodimeric PDGF receptorcomplex correlates with lack of RasGAP binding **Oncogene** 18, 2481-2488

99. Marklund S, Kijas J, Rodriguez-Martinez H, **Rönnstrand L**, Funa K, Moller M, Lange D, Edfors-Lilja I and Andersson L (1998) Molecular basis for the dominant white phenotype in the domestic pig. **Genome Res** 8, 826-833

100. Yokote, K., Hellman, U., Ekman, S., Saito, Y., **Rönnstrand, L.,** Saito, Y., Heldin, C.H. and Mori, S. (1998) Identification of Tyr-762 in the platelet-derived growth factor alpha-receptor as the binding site for Crk proteins **Oncogene** 16, 1229-1239

101. Anthonsen, M.W., **Rönnstrand, L**., Wernstedt, C., Degerman, E. and Holm, C. (1998) Identification of novel phosphorylation sites in hormone sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties *in vitro* **J. Biol. Chem.** 273, 215-221

102. Hansen, K., Alonso, G., Courtneidge, S.A., **Rönnstrand, L.** and Heldin, C.-H. (1997) PDGF-induced phosphorylation of Tyr28 in the N-terminus of Fyn affects Fyn activation. **Biochem. Biophys. Res. Com.** 241, 355-362

103. Kozawa, O., Blume-Jensen, P., Heldin, C.-H. and **Rönnstrand, L.**(1997) Involvement of phosphatidylinositol-3´-kinases in Kit/stem cell factor-induced phospolipase D activation and arachidonic acid release. **Eur. J. Biochem.** 248, 149-155

104. Hansen, K., **Rönnstrand, L.,** Rorsman, C., Hellman, U., and Heldin, C.-H. (1997) Association of coatomer proteins with the beta-receptor for platelet-derived growth factor. **Biochem. Biophys. Res. Comm.** 235, 455-460

105. Hansen, K., **Rönnstrand, L.,** Claesson-Welsh, L. and Heldin, C.-H. (1997) A 72 kDa phosphoprotein forms complex with c-Crk, c-Fyn and Eps15 in PDGF-stimulated cells. **FEBS Lett**. 409, 195-200

106. Kovalenko, M., **Rönnstrand, L**., Heldin, C.-H., Loubchenkov, M., Gazit, A., Levitzki, A., and Böhmer, F.D. (1997) Phosphorylation site-specific inhibition of platelet-derived growth factor receptor autophosphorylation by the receptor blocking tyrphostin AG1296. **Biochemistry** 36, 6260-6269

107. Hansen, K., Johnell, M., Siegbahn, A., Rorsman, C., Engström, U., Wernstedt, C., Heldin, C.-H., and **Rönnstrand, L.** (1996) Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. **EMBO J.** 15, 5299-5313

108. Rahn, T., **Rönnstrand, L**., Leroy, M.-J., Wernstedt, C., Tornqvist, H., Manganiello, V.C., Belfrage, P., and Degerman, E. (1995) Identification of the site in the cGMP-inhibited phosphodiesterase phosphorylated in adipocytes in response to insulin and isoproterenol. **J. Biol. Chem.** 271, 11575-11580

109. Yokote, K., Mori, S., Siegbahn, A., **Rönnstrand, L.**, Wernstedt, C., Heldin, C.-H., and Claesson-Welsh, L. (1995) Structural determinants in the PDGF alpha-receptor implicated in modulation of chemotaxis**. J. Biol. Chem.** 271, 5101-5111

110. Blume-Jensen, P., Wernstedt, C., Heldin, C.-H. and **Rönnstrand, L.** (1995) Identification of the major phosphorylation sites for protein kinase C in Kit/SCF receptor *in vivo* and in intact cells**. J. Biol. Chem.** 270, 14192-14200.

111. Eriksson, A., Nånberg, E., **Rönnstrand, L.**, Engström, U., Hellman, U., Carpenter, G., Heldin, C.-H. and Claesson-Welsh, L. (1995) Demonstration of functionally different interactions between phospholipase Cgamma and the two types of PDGF receptors. **J. Biol. Chem.** 270, 7773-7781

112. Kovalenko, M., Gazit, A., Böhmer, A., Rorsman, C., **Rönnstrand, L**., Heldin, C.-H., Waltenberger, J., Böhmer, F.-D., and Levitzki, A. (1994) Selective PDGF receptor kinase blockers reverse *sis*-transformation. **Cancer Res**. 54, 6106-6114

113. Arvidsson, A.-K., Rupp, E., Nånberg, E., Downward, J., **Rönnstrand, L.,** Wennström, S., Schlessinger, J., Heldin, C.-H. and Claesson-Welsh, L. (1994) Tyr716 in the PDGF beta-receptor kinase insert is involved in GRB2-binding and Ras activation. **Mol. Cell Biol.** 14, 6715-6726

114. Rupp, E., Siegbahn, A., **Rönnstrand, L**., Wernstedt, C., Claesson-Welsh, L., and Heldin, C.-H. (1994) A unique autophosphorylation site in the PDGF alpha-receptor from a heterodimeric receptor complex. **Eur. J. Biochem.** 225, 29-41

115. Blume-Jensen, P., **Rönnstrand, L,** Gout, I., Waterfield, M.D., and Heldin, C.-H. (1994) Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C**. J. Biol. Chem.** 269, 21793-21802

116. Mori, S., **Rönnstrand, L.,** Claesson-Welsh, L., and Heldin, C.-H. (1994) "A tyrosine residues in the juxtamembrane segment of the platelet-derived growth factor beta-receptor is critical for ligand-mediated endocytosis". **J. Biol. Chem**. 269, 4917-4921

117. Blume-Jensen, P., Siegbahn, A., Stabel, S., Heldin, C.-H., and **Rönnstrand, L.** (1993) "Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C". **EMBO J.** 12, 4199-4209

118. Mori, S., **Rönnstrand, L.,** Yokote, K., Engström, Å., Courtneidge, S., Claesson-Welsh, L., and Heldin, C.-H. (1993) "Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor. Involvement in the interaction with Src family tyrosine kinases". **EMBO J.** 12, 2257-2264

119. **Rönnstrand, L.,** Mori, S., Arvidsson, A.-K., Eriksson, A., Wernstedt, C., Hellman, U., Claesson-Welsh, and Heldin, C.-H. (1992) "Identification of two c-terminal autophosphorylation sites in the PDGF beta-receptor. Involvement in the interaction with phospholipase C-gamma". **EMBO J.** 11, 3911-3919

120. Andres, J. L., **Rönnstrand, L**., Cheifetz, S. and Massagué, J. (1991) Purification of the TGF-beta binding proteoglycan betaglycan. **J. Biol. Chem**. 266, 23282-23287

121. Ichijo, H., **Rönnstrand, L**., Miyagawa, K., Ohashi, H., Heldin, C.-H. and Miyazono, K. (1991) Purification of TGF-beta1 binding proteins from porcine uterus membranes". **J. Biol. Chem**. 266, 22459-22464

122. Laiho, M., **Rönnstrand, L**., Heino, J., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M. and Massagué, J. (1991) Control of JunB and extracellular matrix protein expression by transforming growth factor-beta1 is independent of SV 40 T antigen-sensitive growth inhibitory events. **Mol. Cell. Biol.** 11, 972-978

123. **Rönnstrand, L.,** Sorokin, A., Engström, U. and Heldin, C.-H. (1990) Characterization of the platelet-derived growth factor beta-receptor kinase activity by use of synthetic peptides.. **Biochem. Biophys. Res. Comm**. 167, 1333-1340

124. Heldin, C.-H., Ernlund, A., Rorsman, C. and **Rönnstrand, L.** (1989) Dimerization of B type PDGF receptors occurs after ligand binding and is closely associated with receptor kinase activation. **J. Biol. Chem.** 264, 8905-8912

125. Fellström, B., Klareskog, L., Heldin, C.-H., Larsson, E., **Rönnstrand, L.,** Terracio, L., Tufveson, G., Wahlberg, J. and Rubin, K. (1989) Platelet-derived growth factor receptors in the kidney - an upregulated expression in renal inflammation. **Kidney Int.** 36, 1099-1102

126. Terracio, L., **Rönnstrand, L.,** Tingström, A., Rubin, K., Claesson-Welsh, L., Funa, K. and Heldin, C.-H. (1988) Induction of PDGF receptor expression in smooth muscle cells and fibroblasts upon tissue culturing. **J. Cell. Biol.** 107, 1947-1957

127. **Rönnstrand, L.,** Terracio, L., Claesson-Welsh, L., Heldin, C.-H. and Rubin, K. (1988) Characterization of two monoclonal antibodies reactive with the external domain of the platelet-derived growth factor receptor. **J. Biol. Chem**. 263, 10429-10435

128. Rubin, K., Tingström, A., Hansson, G. K., Larsson, E**., Rönnstrand, L**., Klareskog, L., Claesson-Welsh, L., Heldin, C.-H., Fellström, B. and Terracio, L. (1988) Induction of PDGF B-type receptors in vascular inflammation: possible implications for the development of vascular proliferative lesions. **Lancet** 1, 1353-1356

129. Heldin, C.-H., Bäckström, G., Östman, A., Hammacher, A., **Rönnstrand, L**., Rubin, K., Nistér, M. and Westermark, B. (1988) Binding of different dimeric forms of PDGF to human fibroblasts: evidence for two separate receptor types. **EMBO J.** 7, 1387-1393

130. Nistér, M., Hammacher, A., Mellström, K., Siegbahn, A., **Rönnstrand, L.**, Westermark, B. and Heldin, C.-H. (1988) A glioma-derived PDGF A chain homodimer has different functional activities than a PDGF AB heterodimer purified from human platelets. **Cell** 52, 791-799

131. Rubin, K., Terracio, L., **Rönnstrand, L**., Heldin, C.-H. and Klareskog, L. (1988) Expression of platelet-derived growth factor receptors is induced on connective tissue cells during chronic synovial inflammation. **Scand. J. Immunol**. 27, 285-294

132. Claesson-Welsh, L., **Rönnstrand, L.,** and Heldin, C.-H (1988) Biosynthesis and intracellular processing of the receptor for platelet-derived growth factor. **Proc. Natl. Acad. Sci. USA** 84, 8796-8800

133. Fellström, B., Klareskog, L., Larsson, E., Tufveson, G., Wahlberg, J., **Rönnstrand, L.**, Heldin, C.-H., Terracio, L., and Rubin, K. (1987) Tissue distribution of macrophages, class II transplantation antigens, and receptors for platelet-derived growth factor in normal and rejected human kidneys. **Transplant. Proc**. 19, 3625-3627

134. **Rönnstrand, L.,** Beckmann, M.P., Faulders, B., Östman, A., Ek, B., and Heldin, C.-H. (1987) Purification of the receptor for platelet-derived growth factor from porcine uterus. **J. Biol. Chem**. 262, 2929-2932

135. Heldin, C.-H., Ek, B., and **Rönnstrand, L**. (1983) Characterization of the receptor for platelet-derived growth factor on human fibroblasts. Demonstration of an intimate relationship with a 185,000-Dalton substrate for the platelet-derived growth factor-stimulated kinase.. **J. Biol. Chem**. 258, 10054-10061

Reviews and chapters in books

1. Kabir NN, **Rönnstrand L** and Kazi JU (2017) GRB10. In: Encyclopaedia of Signaling Molecules, 2nd Edition. Springer. p. 1-4. DOI 10.1007/978-1-4614-6438-9_101665-1

2. Moharram SA, **Rönnstrand L** and Kazi JU (2017) Src-like adapter protein (SLAP). In: Encyclopaedia of Signaling Molecules, 2nd Edition. Springer.

3. Moharram SA, **Rönnstrand L** and KAZI JU (2017) Src-like adapter protein 2 (SLAP2). In: Encyclopaedia of Signaling Molecules, 2nd Edition. Springer.

4. Rupar K, Kazi JU and **Rönnstrand L** (2017) Stem cell factor receptor (KIT). In: Encyclopaedia of Signaling Molecules, 2nd Edition. Springer.

5. Kazi JU, Moharram SA and **Rönnstrand L** (2017). FMS-like tyrosine kinase-3 (FLT3). In: Encyclopaedia of Signaling Molecules, 2nd Edition. Springer.

6. Kazi JU, Kabir NN and **Rönnstrand L** (2017) Brain expressed x-linked 3 (BEX3). In: Encyclopaedia of Signaling Molecules, 2nd Edition. Springer.

7. Kazi JU, Kabir NN and **Rönnstrand L** (2015) Brain-Expressed X-linked (BEX) proteins in human cancer. **BBA Reviews on Cancer**. 1856, 226-33

8. Lennartsson J and **Rönnstrand L** (2015) The KIT receptor tyrosine kinase. In: **Receptor Tyrosine Kinase: Family and Subfamilies**. Eds. Deric Wheeler and Yosef Yarden, Springer Science.

9. Sun J, Scheding S and **Rönnstrand L** (2015) Mesenchymal – Development and Regeneration Potential. **The SAGE Encyclopedia of Stem Cell Research**, Second Edition, SAGE Publications, Inc. 752-755, DOI: 10.4135/9781483347660.n278

10. Sun J, Scheding S and **Rönnstrand L** (2015) Mesenchymal Stem Cells. **The SAGE Encyclopedia of Stem Cell Research**, Second Edition, SAGE Publications, Inc. 762-764, DOI: 10.4135/9781483347660.n282

11. Kazi J. U., Kabir N. N., and **Rönnstrand L.** (2015) Drug Testing and Drug Development in Cell Culture. **The SAGE Encyclopedia of Stem Cell Research**, Second Edition, SAGE Publications, Inc. 363-366, DOI: 10.4135/9781483347660.n133

12. Kazi J. U., Sun J. and **Rönnstrand L.** (2015) Fluorescent Activated Cell Sorting. The SAGE Encyclopedia of Stem Cell Research, Second Edition, SAGE Publications, Inc. 418-420, DOI: 10.4135/9781483347660.n153

13. Lindblad O., Kazi J. U., **Rönnstrand L.** (2015) Bone marrow transplants. **The SAGE Encyclopedia of Stem Cell Research**, Second Edition, SAGE Publications, Inc. 129-132, DOI: 10.4135/9781483347660.n50

14. Kazi JU, Kabir NN, **Rönnstrand L.**(2015) Role of SRC-like adaptor protein (SLAP) in immune and malignant cell signaling. **Cell Mol Life Sci** 72, 2535-44

15. Kazi, JU, Flores-Morales, A and **Rönnstrand L** . (2015) SOCS6 (Suppressor of Cytokine Signaling 6). **Atlas of Genetics and Cytogenetics in Oncology and Haematology** 19, 50-52

16. Kabir NN, Sun J, **Rönnstrand L** and Kazi JU (2014) SOCS6 is a selective suppressor of receptor tyrosine kinase signaling. **Tumor Biology**. 35,10581-9

17. Kazi JU, Kabir NN, Flores-Morales A, and **Rönnstrand L** (2014) SOCS proteins in regulation of receptor tyrosine kinase signaling. **Cell Mol Life Sci** 71, 3297-3310

18. Kazi JU, Kabir NN and Rönnstrand L (2013) Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia. **Med Oncol**. 30, 757

19. Lennartsson J and **Rönnstrand L** (2012) Stem cell factor receptor/c-Kit: from basic science to clinical implications. **Physiol Rev** 92, 1619-49

20. **Rönnstrand L** (2011) Signaling by the Platelet-Derived Growth Factor Receptor Family. In: "**Functioning of transmembrane receptors in Cell signaling**" Eds. R.A. Bradshaw and E.A. Dennis. Chapter 17, pp. 117-124. Academic Press. ISBN 9780123822116

21. **Rönnstrand L.** (2009) Signaling by the Platelet-Derived Growth Factor Receptor Family. In: "**Handbook of Cell Signaling**. Vol 2., Chapter 60, pp 427-434 2nd Ed. Elsevier. ISBN 978-0-12-374145-5

22. Masson K and **Rönnstrand L.** (2009) Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3" **Cell Signal** 21, 1717-26

23. Lennartsson, J. and **Rönnstrand, L**. (2006) The stem cell factor receptor/c-Kit as a drug target in cancer. **Current Cancer Drug Targets** 6, 65-75

24. Lennartsson, J., Voytyuk, O., Heiss, E., Sundberg, C., Sun, J. and **Rönnstrand, L.** (2005) C-Kit signal transduction and involvement in cancer. **Cancer Ther**. 3, 5-28

25. **Rönnstrand, L.** (2004) Signal transduction via the stem cell factor receptor/c-Kit. **Cell Mol Life Sci.** 61, 2535-2548

26. **Rönnstrand, L.** and Heldin, C.-H. (2001) Mechanisms of platelet-derived growth factor-induced chemotaxis. **Int. J. Cancer** 91, 757-762

27. Souchelnytskyi, S., **Rönnstrand, L.**, Heldin, C.-H. and ten Dijke, P. Phosphorylation of Smad signalling proteins by receptor serine/threonine kinases. In: "Protein Kinase Protocols" (Methods in Molecular Biology Series, Vol. 124, pp. 107-120; 2001).

28. Heldin, C.-H., Östman, A., and **Rönnstrand, L**., Signal transduction via PDGF receptors. **BBA Cancer Reviews** 1378, F79-F113. 1998

29. Heldin, C.-H. and **Rönnstrand, L**. Growth factor receptors in cell transformation. In: Oncogenes and tumour suppressor genes. Eds.: G. Peters and K. Vousden. Oxford University Press. 1997. P. 55-85. ISBN 978-0-19-963594-8

30. **Rönnstrand, L**. and Heldin, C.-H. Purification of the platelet-derived growth factor beta-receptor from porcine uterus. Meth. Enzymol., 1991, 200, 371-378

31. **Rönnstrand, L**. Purification, characterization and studies on the *in vivo* distribution of the B-type receptor for platelet-derived growth factor. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, Upppsala Universitet, Reprocentralen HSC, Uppsala 205, pp.1.64

32. Heldin, C. -H. and **Rönnstrand, L**. Platelet-derived growth factor B type receptor. In: Receptor Purification. Vol 1. Pp 303-314 Ed.: G. Litwack. Humana Press Inc., 1988 ISBN *978-0-89603-167-8*

33. Heldin, C.-H. and **Rönnstrand, L**. The platelet-derived growth factor receptor. In: Receptor phosphorylation. Pp 149-162 Ed. : V. K. Moudgil. CRC Press. 1988 ISBN 9780849363184

34. Heldin, C.-H., Johnsson, A., Ek, B., Wennergren, S., **Rönnstrand, L**., Hammacher, A., Faulders, B., Wasteson, Å. and Westermark, B. Purification of human platelet-derived growth factor. Meth. Enzymol., 1987, 147, 3-13

35. Heldin, C.-H., Betsholtz, C., Johnsson, A., Nistér, M., Ek, B., **Rönnstrand, L.,** Wasteson, Å., and Westermark, B. Platelet-derived growth factor - mechanism of action and relation to oncogenes. J. Cell. Sci. Suppl. 1985, 3, 65-76

36. Ek, B., **Rönnstrand, L.** and Heldin, C.-H. Stimulation of tyrosine phosphorylation by platelet-derived growth factor. Biochem. Soc. Trans.,1984, 12, 759-762

37. Heldin, C.-H., Westermark, B., Mellström, K., Johnsson, A., Ek, B., Nistér, M., Betsholtz, C., **Rönnstrand, L.** and Wasteson, Å. Platelet-derived growth factor – structural and functional aspects. Surv. Synth. Path. Res. 1983, 1, 154-164

38. Heldin, C.-H., Ek, B. and **Rönnstrand, L.** Characterization of the fibroblast receptor for platelet-derived growth factor. Cell. Biol. Intn. Rep., 1983, 7, 543-544